7-р сарын 2022: Emergen Research-ийн хийсэн хамгийн сүүлийн үеийн судалгаагаар 1.29 онд CAR T-эсийн эмчилгээний дэлхийн зах зээл 2021 тэрбум ам.долларт хүрч, таамагласан хугацаанд CAGR 24.9 хувийн орлоготой байх төлөвтэй байна. Дэлхий даяар хорт хавдрын өвчлөл нэмэгдэж, хорт хавдрын улмаас нас баралтын түвшин нэмэгдэж байгаа нь урьдчилсан хугацаанд CAR-T эсийн эмчилгээний дэлхийн зах зээлийн орлогын өсөлтийн гол хүчин зүйл байх төлөвтэй байна. Эмнэлзүйн туршилтын үйл ажиллагаа асар хурдацтай өргөжин тэлж, нэгдэл, худалдан авалт олширч, олон нийтэд анхдагч зах зээлд нийлүүлэх сонирхол татсан зэрэг нь CAR T эсийн эмчилгээний дэлхийн зах зээл дэх орлогын өсөлтөд нөлөөлж буй хүчин зүйлүүд юм.
The primary objective of the report is to provide an overview of the market, including product scope, growth prospects, and potential risks. In-depth information about each participant in the global CAR T-Cell эмчилгээ market, including that participant’s global standing, financial status, product launch, and business expansion plans, is included in the report. The participants in the market are concentrating their efforts on the creation of a variety of strategies, including partnerships, mergers and acquisitions, joint ventures, product launches, and investments in research and development.
According to the findings of the study, there are certain types of dangers and difficulties that can serve as an obstacle for a company. Granularity can be added to the overall research by performing an in-depth analysis of the CAR T-Cell эмчилгээ market in the context of various aspects of the larger environment, such as the social, political, economic, and technological settings. In addition, the study generates real-time data on essential aspects such as sales, profits, gross margin, and growth prospects to demonstrate how going forward the company will see a significant upswing in its performance.
Тайлангаас гарсан нэмэлт чухал дүгнэлтүүд үүнийг харуулж байна
2021 онд сарнисан том В эсийн сегмент лимфома was responsible for the majority of the rapid revenue share. A cancer of the lymphatic system, which is an essential component of the immune system, called diffuse large B-cell lymphoma has a rapid growth rate. It has an effect on the blood cells that generate antibodies, which are used to fight infections. In certain instances, DLBCL can be cured. The majority of patients suffering from DLBCL have a favourable response to initial treatments such as chemotherapy. In the case of some people, the illness either becomes resistant to treatment, which means that it no longer responds to it, or it relapses, which means that it returns after treatment has been completed. These patients may be candidates for treatment with химерик антиген рецепторын Т эсийн эмчилгээ, which utilises the patient’s own immune cells in the fight against DLBCL. T-cells are taken out of the patient’s blood, modified in the laboratory with so-called chimeric antigen receptors that help in recognising and destroying cancer cells, and then reintroduced into the patient’s blood again. This process is repeated several times.
In 2021, the hospital segment was responsible for a fair amount of the total revenue. The CAR T-cell therapy will reprogramme the patient’s T-cells so that they will target the antigens produced by the tumour. CAR T-cell therapy has shown full remission rates of 80 to 90 percent in younger patients with B-cell acute lymphoblastic leukaemia, and it has shown a full remission rate of 40 percent in patients with symptomatic B-cell Ходгкин бус лимфома who have failed several prior lines of therapy. Both of these patient populations have B-cell acute lymphoblastic leukaemia.
Одоогийн байдлаар зах зээлд үйл ажиллагаа явуулж буй гол компаниудыг компанийн танилцуулга, бүтээгдэхүүний багц, өргөжүүлэх стратеги, стратегийн холбоо зэрэг нь энэхүү тайланд нарийвчлан судалсан болно. Эдгээр төрлийн холбоодын зарим жишээнд нэгдэх, худалдан авах, хамтын ажиллагаа, хамтарсан үйлдвэрүүд орно. Нэмж дурдахад компанийн ололт амжилт, санхүүгийн байдлын талаар онцлох мэдээллүүд, мөн компанийн зах зээлийн цар хүрээ, дэлхийн хэмжээнд эзлэх байр суурийг харуулсан болно.
Дэлхийн CAR T-Cell Therapy зах зээлд нэрлэгдсэн компаниуд:
Novartis AG, Pfizer Inc., CARsgen Therapeutics Co., Ltd, Daiichi Sankyo Company, Limited, Bristol-Myers Squibb Company, Astellas Pharma Inc., BioNTech SE, Biocad, F. Hoffmann-La Roche Ltd., Eli Lilly and Company .
Дэлхийн CAR T-Cell Therapy зах зээлийн тайлангийн талаар дэлгэрэнгүй уншина уу: https://www.emergenresearch.com/industry-report/car-t-cell-therapy-market
